On Nov. 5, 2021, NRx Pharmaceuticals reported a safety update on ZYESAMIﾮ (aviptadil), which was being tested in the ACTIV-3b Critical Care Phase 3 study sponsored by the National Institutes of Health.

In its third scheduled analysis, the study’s Independent Data Safety Monitoring Board found no new safety concerns after reviewing a total of more than 300 patients and recommended continued enrollment.